英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
palatin查看　palatin　在百度字典中的解释百度英翻中〔查看〕
palatin查看　palatin　在Google字典中的解释Google英翻中〔查看〕
palatin查看　palatin　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Palatin Technologies | Home
    At Palatin, we drive our culture with science Our employees have unparalleled expertise related to the melanocortin system allowing them to develop potent, selective treatments for patients with unmet medical needs
  • Palatin Technologies | Pipeline
    Palatin is developing a truly novel class of drugs that selectively bind to melanocortin receptors (MCR), with both MCR1 and pan-agonists, to directly activate natural pathways that resolve disease inflammation in the eye
  • Palatin Technologies | About Us
    Robert has successfully managed several drug programs, including Palatin’s development of Vyleesi ® from phase 2 through NDA submission and FDA approval in 2019 as the only as-needed treatment for hypoactive sexual desire disorder (HSDD) Robert oversees all of Palatin’s drug development programs as well as leads clinical operations
  • Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical . . .
    Palatin will host a conference call and audio webcast on February 28, 2024, at 8:30 a m Eastern Time to discuss the PL9643 Phase 3 clinical study results in greater detail Individuals interested in listening to the conference call live can dial 1-888-506-0062 (US) or 1-973-528-0011 (International), Participant Access Code: 295124
  • Palatin Provides Update on Anticipated 2025 Corporate Milestones
    CRANBURY, N J , Jan 28, 2025 PRNewswire — Palatin Technologies, Inc (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system (MCRS), today provided an update on anticipated corporate milestones expected to occur in calendar year
  • Palatin Technologies Announces Pricing of up to $23 Million Public . . .
    CRANBURY, N J , May 7, 2025 PRNewswire — Palatin Technologies, Inc (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the pricing of its public offering with
  • Palatin Technologies | Press Releases
    Press releases issued by Palatin are accessible below These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships
  • Palatin Presents Promising Preclinical Data for Melanocortin Agonist . . .
    The poster, titled “Activation of the Melanocortin System Increases Aqueous Outflow, Reduces Intraocular Pressure (IOP), and Protects Neurons in Glaucoma Models,” was presented on May 4 by Dr Alison Obr of Palatin The full poster is available at www palatin com
  • Palatin Reports First Quarter Fiscal Year 2025 Operating Financial . . .
    CRANBURY, N J , Nov 14, 2024 PRNewswire — Palatin Technologies, Inc (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced operating and financial results for its fiscal first quarter ended September 30, 2024





中文字典-英文字典  2005-2009